Solasia Pharma KK

As of June 30, 2026, Solasia Pharma KK carries a market capitalization of 7.10B, placing it among publicly traded companies globally. Its enterprise value stands at 5.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Solasia Pharma KK's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Solasia Pharma KK has 273.01M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Solasia Pharma KK maintains a current ratio of 4.28, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Solasia Pharma KK's stock has declined approximately 25.71% over the past 52 weeks. The 50-day moving average sits at 29.96, while the 200-day moving average is 29.50.

As of June 30, 2026, Solasia Pharma KK holds 1.29B in cash and equivalents against 78.00M in total debt, resulting in a net debt position of -1.29B. Total book value stands at 1.45B, with working capital of 1.24B providing operational flexibility.